Replimune
1D
1W
1M
3M
1Y
5Y
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3.
CEOPhilip Astley-Sparke
CEOPhilip Astley-Sparke
Employees206
Employees206
HeadquartersWoburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded2015
Founded2015
Employees206
Employees206
REPL Key Statistics
Market cap991.06M
Market cap991.06M
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume301.41K
Average volume301.41K
High today$20.07
High today$20.07
Low today$19.31
Low today$19.31
Open price$19.50
Open price$19.50
Volume107.22K
Volume107.22K
52 Week high$31.19
52 Week high$31.19
52 Week low$13.05
52 Week low$13.05
REPL News
Benzinga 6d
Replimune to Host Virtual Investor Event on December 7, 2022 - Replimune Group - BenzingaWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class o...
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
REPL Earnings
-$1.75
-$1.17
-$0.58
$0.00
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Q2 FY23
Q3 FY23
Estimated— per share
Estimated— per share
ActualExpected Feb 2, Pre-Market
ActualExpected Feb 2, Pre-Market